Purespring Therapeutics Series B financing - Sharecast.com

Oct 9, 2024 · *A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: Obtains access to the information in a personal capacity;

CouponFollow Extension

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

London – 9 October 2024 – Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

purespringtx.com

£80
OFF

Syncona's Purespring Raises £80m In New Financing

6 days from now

Oct 9, 2024 · Life science investor Syncona said its portfolio company Purespring Therapeutics, which focuses on gene therapies for kidney diseases, had raised £80m in an oversubscribed …

sharecast.com

$105
OFF

Purespring Therapeutics Secures £80/$105M In Series B Funding …

6 days from now

Oct 9, 2024 · Purespring Therapeutics has raised £80/$105 million in a Series B financing round, led by Sofinnova Partners and featuring other prominent investors, to advance its gene …

ainvest.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

yahoo.com

£80
OFF

Purespring Therapeutics Series B Financing

6 days from now

9 October 2024 . Syncona Limited . Purespring Therapeutics raises £80 million in a Series B financing · Purespring raises £80 million in a Series B financing, with Syncona committing …

londonstockexchange.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

Oct 9, 2024 · Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases. Oversubscribed financing led by Sofinnova Partners in …

businessinsider.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

biospace.com

£80
OFF

Purespring Therapeutics Series B Financing – Company …

6 days from now

9 October 2024 Syncona Limited Purespring Therapeutics raises £80 million in a Series B financing · Purespring raises £80 million in a Series B financing, with Syncona committing …

ft.com

$104711631
OFF

Series B - Purespring Therapeutics - 2024-10-09 - Crunchbase

6 days from now

Oct 9, 2024 · Purespring Therapeutics raised $104711631 on 2024-10-09 in Series B. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. ... GlobeNewswire …

crunchbase.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

Oct 9, 2024 · Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised £80/$105 million …

icheme.org

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

yahoo.com

$105
OFF

Purespring Bottles Up $105M Series B For Kidney Gene Therapy

6 days from now

Oct 9, 2024 · London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of a new £80 million (about $105 million) pool of series …

fiercebiotech.com

$105
OFF

Purespring Therapeutics Presents New Preclinical Data On Novel …

6 days from now

London – 28 October 2024 – Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, ... ($105 million) in a Series B …

purespringtx.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

Oct 9, 2024 · Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases. Oversubscribed financing led by Sofinnova Partners in …

tmcnet.com

$105
OFF

Purespring Therapeutics Raises £80M In Series B Round To Launch …

6 days from now

Oct 9, 2024 · NEW YORK – Purespring Therapeutics on Wednesday announced that it has raised £80 million ($105 million) in an oversubscribed Series B financing round, which it plans to use …

precisionmedicineonline.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In Series B …

6 days from now

London, 7 October, 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised £80/$105 …

forbion.com

£80
OFF

Purespring Therapeutics | Pre-clinical Companies | Portfolio

6 days from now

Raised in a Series B in October 2024 £80m. Unless stated all financials at 30 September 2024. ... Purespring Therapeutics and Beacon Therapeutics. He previously also supported Nightstar …

synconaltd.com

FAQs about Purespring Therapeutics Series B financing - Sharecast.com Coupon?

Does purespring therapeutics have a series B financing?

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde Healthcare, Forbion, British Patient Capital and founding investor Syncona ...

Who owns purespring Therapeutics?

Michael Kyriakides, Investment Partner at Syncona Investment Management and Board Director of Purespring Therapeutics, said: “Syncona founded Purespring with the vision of creating the world’s leading kidney gene therapy company, and we have been impressed with its progress. ...

Will purespring bring kidney-tweaking gene therapy to the clinic?

London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of a new £80 million (about $105 million) pool of series B cash. ...

What will purespring do with proceeds from a Phase I/II clinical trial?

Proceeds will be used to support Purespring’s pipeline including the initiation of a Phase I/II clinical trial for IgA Nephropathy (IgAN), a common, chronic kidney disease primarily affecting young adults. About one third of IgAN patients will go on to lose their kidney function within five years and require a kidney transplant or dialysis. ...

What is purespring AV gene therapy?

Purespring is one of the first AAV gene therapy companies focused on the kidney globally and will seek to treat a number of debilitating chronic diseases that are currently poorly addressed with existing therapies. ...

What is purespring?

Purespring seeks to advance gene therapies for the treatment of chronic renal diseases that are currently poorly addressed with existing treatments. ...